Edwards Lifesciences (EW) Receivables - Net (2016 - 2025)
Edwards Lifesciences (EW) has 17 years of Receivables - Net data on record, last reported at $659.6 million in Q4 2025.
- For Q4 2025, Receivables - Net rose 8.29% year-over-year to $659.6 million; the TTM value through Dec 2025 reached $659.6 million, up 8.29%, while the annual FY2025 figure was $659.6 million, 8.29% up from the prior year.
- Receivables - Net reached $659.6 million in Q4 2025 per EW's latest filing, down from $693.3 million in the prior quarter.
- Across five years, Receivables - Net topped out at $817.6 million in Q1 2024 and bottomed at $582.2 million in Q4 2021.
- Average Receivables - Net over 5 years is $678.4 million, with a median of $664.4 million recorded in 2025.
- Peak YoY movement for Receivables - Net: increased 19.98% in 2023, then decreased 21.05% in 2024.
- A 5-year view of Receivables - Net shows it stood at $582.2 million in 2021, then grew by 10.44% to $643.0 million in 2022, then rose by 19.98% to $771.5 million in 2023, then decreased by 21.05% to $609.1 million in 2024, then increased by 8.29% to $659.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $659.6 million in Q4 2025, $693.3 million in Q3 2025, and $697.0 million in Q2 2025.